Rein Therapeutics shares surge 10.66% after-hours as Voss Capital buys $127K stake and reports positive LTI-03 clinical results.

Rein Therapeutics surged 10.66% in after-hours trading, driven by multiple positive catalysts. The stock’s rally followed Voss Capital’s $127.6K purchase of 104,183 shares, signaling investor confidence, and the company’s announcement of positive clinical findings from a dose-escalation study for its lead IPF candidate, LTI-03. Additionally, the FDA lifted a clinical hold on the Phase 2 RENEW trial, while European regulatory approval expanded the study to Germany and Poland. Analyst upgrades from H.C. Wainwright (Buy, $10 target) and Brookline Capital (Buy, $6 target) further reinforced optimism. These developments, coupled with a $1M upfront payment from Yorkville under a financing agreement, collectively fueled the after-hours surge.